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Background: Reduced β2-glycoprotein I (reduced β2GP I), which has free sulfhydryl groups, is present in plasma
and serum; it can protect vascular endothelial cells from damage due to oxidative stress in vitro. We investigated
the effects of reduced β2GP I on the expression of various matrix metalloproteinases (MMPs) and tissue inhibitors of
matrix metalloproteinases (TIMPs) in the aortas of diabetic mice.
Methods: We provided 120 female 8-week-old Balb/c mice with a high sugar, high fat diet. After 8 weeks they were
injected with streptozotocin to induce diabetes. We treated mice in the mono dose groups with β2GP I, reduced
β2GP I, or phosphate-buffered saline (PBS) on day 1 and fed them for 3 weeks. The mice in the complex dose
groups were treated with β2GP I, reduced β2GP I, or PBS on days 1 and 22 and fed for 6 weeks. Control mice were
given a standard chow diet. Blood lipids were measured at the end of 3 or 6 weeks, and aortas removed to observe
morphological and molecular biological changes.
Results: The low-density lipoprotein cholesterol levels in mice of the reduced β2GP I group were lower than those
in the diabetic group. Aortic lipid deposition in the reduced β2GP I group was significantly less than in the diabetic
control group. In the aortas, reduced β2GP I decreased MMP2/TIMP2 mRNA and protein expression levels, and
MMP9/TIMP1 expression levels compared with those in diabetic controls. Reduced β2GP I down-regulated p38
mitogen-activated protein kinase (p38MAPK) mRNA expression and phosphorylated p38MAPK protein expression
compared with those in diabetic controls of the complex dose group.
Conclusions: Reduced β2GP I plays a role in diabetic mice related to vascular protection, inhibiting vascular lipid
deposition, and plaque formation by reducing MMPs/TIMPs expression through down-regulation of the p38MAPK
signaling pathway.
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The latest epidemiological data show that the prevalence
of diabetes is 11.6%, and pre-diabetes is 50.1%, in people
over 18 years old in China [1]. The macrovascular com-
plications of diabetes mainly cause damage to the car-
diovascular system. Diabetes is related to a higher risk of* Correspondence: wbyp1998@hotmail.com; yudmdm@163.com
2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics,
the Key Laboratory of Hormones and Development (Ministry of Health),
Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin
Medical University, No.66 Tong-An Road, Heping district, 300070 Tianjin,
China
© 2014 Xu et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.coronary heart disease, especially in patients who have
had diabetes for more than 10 years [2]. Patients with
diabetes are also more prone to atherosclerosis and car-
diovascular events (angina, myocardial infarction, heart
failure) [3,4]. However, the pathogenesis of diabetes has
not been fully elucidated. β2-glycoprotein I (β2GP I) is a
phospholipid-binding plasma protein, and an autoanti-
gen. In patients with type 2 diabetes or myocardial
infarction, plasma β2GP I and oxidized low-density lipo-
protein (oxLDL)/β2GP I complex levels are significantly
increased; these are predicted adverse consequences ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Primer sequence of TIMP-1, −2, MMP2, MMP9,
p38MAPK and GAPDH for real time PCR
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http://www.biomedcentral.com/1471-2261/14/114cardiovascular events [5]. Previous studies have shown
that β2GP I/oxLDL/C reactive protein (CRP) complexes
can up-regulate the expression of p38MAPK, increasing
the generation of atherosclerosis in diabetic mice [6]. Re-
duced β2GP I, which has free sulfhydryl groups, is also
present in plasma and serum; it can protect endothelial
cells from damage due to oxidative stress [7]. Matrix
metalloproteinases (MMPs) can degrade all extracellular
matrix components, resulting in their increased activity
in the aortic plaque. They can then degrade collagen fi-
bers, making the fibrous cap thin and plaques easily
broken. Type IV collagen is an important component of
the basement membrane in atherosclerotic plaques and
fibrous caps. Gelatinases (MMP2, MMP9) responsible
for its degradation encourage smooth muscle cells to
migrate into the intima membrane and accelerate ath-
erosclerosis, leading to unstable plaque formation [8].
Oxidative stress is present in diabetes, and elevated
levels of reactive oxygen species can lead to elevated
MMP2 and MMP9 levels [9]. Tissue inhibitors of matrix
metalloproteinases (TIMPs) are natural inhibitors of
MMPs; TIMP-1 can inhibit MMP9, while TIMP-2 can
inhibit MMP2. The TIMPs are known suppressors of
atherosclerosis [10,11]. Previous studies have shown that
reduced β2GPI can inhibit the formation of foam cells
by macrophages and apoptosis in vitro [12]. The aim ofTable 2 Changes in blood glucose and body weight
Groups n Blood glucose (
Mono dose
β2GP I 40 24.11 ± 7.54*
Reduced β2 GP I 40 24.07 ± 11.20*
Diabetic control 40 26.07 ± 4.42*
Normal control 40 7.40 ± 1.12
*P < 0.05 vs. normal control.our study was to investigate how reduced β2GP I by
MMPs/TIMPs affect the aorta in vivo, and to determine
any related mechanisms of action involved.
Methods
Animal models and groups
All animal experiments were approved by the Animal
Care and Research Committee of Tianjin Medical
University. All procedures were performed in accordance
with the Guidelines of Animal Experiments from the
Committee of Medical Ethics, the National Health
Department of China (1998). We obtained 160 female
Balb/c mice (8 weeks old) weighing 18–25 g were ob-
tained from the Peking University Experimental Animal
Center. We randomly selected 40 mice as the normal
control group; these mice were given a standard chow
diet for 8 weeks and injected with sodium citrate buffer.
The remaining 120 mice were given a high sugar and
high fat diet (10% sugar, 10% lard, 5% yolk, 1% choles-
terol, and 0.2% bile salt by mg) for 8 weeks. These mice
were then intraperitoneally injected with 80 mg/kg of 2%
streptozotocin twice. Tail vein blood glucose levels were
measured one week later; mice with a blood glucose con-
centration ≥ 16.7 mM were considered diabetes.
Diabetic mice were randomly divided into six groups
(n = 20 mice per group). There were three mono-dose
groups that were injected once in the tail vein on day 1:
the β2GP I group (20 μg); the reduced β2GP I group
(20 μg); and the diabetic control group treated with
phosphate-buffered saline (PBS). We used PBS as the ve-
hicle for β2GP I and reduced β2GP I. We also had three
complex-dose groups that were injected twice in the tail
vein on days 1 and 22: the β2GP I group (20 μg each
injection), the reduced β2GP I group (20 μg each injec-
tion); and the diabetic control group (PBS). The 40
normal control mice were randomly divided into two
groups (n = 20 mice per group), so that there were
controls for the mono- and complex-dose groups, and
injected with PBS.
Body weight and blood glucose
Body weight was assessed every week. Following injec-
tion with streptozotocin, blood glucose levels were mon-
itored weekly.mM) Body weight (g)
Complex dose Mono dose Complex dose
20.86 ± 6.96* 26.13 ± 2.36 25.85 ± 3.32
18.19 ± 6.43* 25.50 ± 3.42 27.10 ± 2.90
19.00 ± 7.75* 23.67 ± 3.20 24.60 ± 3.34
5.93 ± 0.79 24.67 ± 2.08 27.73 ± 2.97
Figure 1 Blood lipid changes in each group. We obtained 160 female Balb/c mice (8 weeks old) and randomly selected 40 mice as the
normal control group, which were given a standard chow diet for 8 weeks. The remaining 120 mice were given a high sugar and high fat diet
for 8 weeks. These mice were then intraperitoneally injected with 80 mg/kg of 2% streptozotocin twice. Mice with a blood glucose concentration ≥ 16.7
mM were considered diabetes. Diabetic mice were randomly divided into six groups (n = 20 mice per group). There were three mono-dose groups that
were injected once in the tail vein on day 1: the β2GP I group (20 μg); the reduced β2GP I group (20 μg); and the diabetic control group treated with PBS.
We used PBS as the vehicle for β2GP I and reduced β2GP I. We also had three complex-dose groups that were injected twice in the tail vein on days 1 and
22: the β2GP I group (20 μg each injection), the reduced β2GP I group (20 μg each injection); and the diabetic control group (PBS). The 40 normal control
mice were randomly divided into two groups (n = 20 mice per group), so that there were controls for the mono- and complex-dose groups, and injected
with PBS. The blood lipids were tested at day 22 in mono-dose groups and at day 43 in complex-dose groups. A. Plasma concentration of triglycerides
(TG). B. Plasma concentration of total cholesterol (TC). C. Plasma concentration of low-density lipoprotein cholesterol (LDL-c). D. Plasma concentration of
high-density lipoprotein cholesterol (HDL-c). Values are presented as mean ± SD. *P < 0.05 vs. normal controls; #P < 0.05 vs. diabetic controls; @P < 0.05 vs.
reduced β2GP I (R-β2GP I); and &P < 0.05 vs. β2GP I.
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Blood from mice in the mono-dose groups were sampled
at day 22, and at day 43 for those in the complex-dose
groups. Blood was obtained via retro-orbital plexus and
mice were sacrificed by cervical dislocation. Aortas were
carefully dissected from the iliac bifurcation to the aortic
arch and external fatty deposits were removed. Complete
aortas were then collected.
Determination of serum lipids
Blood samples were centrifuged (3500 rpm, 5 min,
room temperature) and the plasma concentration of
triglycerides, total cholesterol, low density lipoprotein
cholesterol (LDL-c), and high-density lipoprotein choles-
terol (HDL-c) were determined by enzymatic colorimetric
assays using an Automatic Biochemical Analyzer (Hitachi
Co., Japan).
Aortic lipid analysis
Aortas were fixed in 4% (w/v) paraformaldehyde over-
night and cut open longitudinally. After rinsing in 70%(v/v) ethanol, specimens were stained with Sudan IV so-
lution for 15 min and decolorized in 80% (v/v) ethanol
for 20 min until the normal tissue turned white. Neutral
resins were used to block specimens. Images were ac-
quired using a PowerShot S70 camera (Canon, Japan)
and analyzed with ImageJ 2.1.4.7 (National Institutes of
Health, USA). We then calculated the percentage of
plaque coverage.Histopathology analysis
Paraffin-embedded aortas were serially sectioned (5 μm
thickness) and deparaffinized with dimethylbenzene (2 ×
15 min), then treated with absolute ethanol (2 × 5 min),
washed with distilled water, and stained with hematoxylin
and 0.5% eosin. Aortas were washed with distilled water,
then placed through a graded series of ethanol [80, 95 and
100% (v/v)], incubated with dimethylbenzene (2 × 2 min),
and blocked with neutral resins. Sections were observed
using microscopy to compare histopathological alterations
in the various groups.
Figure 2 Aortic lipid staining with Sudan IV. A. Aortas were fixed in 4% (w/v) paraformaldehyde overnight and cut open longitudinally. After
rinsing in 70% (v/v) ethanol, specimens were stained with Sudan IV solution for 15 min and decolorized in 80% (v/v) ethanol for 20 min until
the normal tissue turned white. Neutral resins were used to block specimens. Images were acquired using camera and analyzed with ImageJ. We then
calculated the percentage of plaque coverage. Red staining is indicative of lipid deposition. B. Lipid area/total vessel area for five aortas selected from each
group. *P < 0.05 vs. normal controls; #P < 0.05 vs. diabetic controls; @P < 0.05 vs. reduced β2GP I (R-β2GP I); and &P < 0.05 vs. β2GP I.
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The oligonucleotide primer sequences for amplifica-
tion and quantitation of TIMP-1, TIMP-2, MMP2,
MMP9, p38MAPK, and glyceraldehyde-3-phosphate
dehydrogenase (GADPH) are presented in Table 1.
Total RNA was isolated using Trizol (Sigma-Aldrich,
USA). We used a reverse transcription kit to synthesize
RNA into cDNA. For quantitative polymerase chain re-
action assays, each reaction comprised 5 μL of SYBR®
Green II, 0.4 μL of each downstream and upstream,
1 μL of cDNA, and 3.2 μL of diethylpyrocarbonate-treated
water. Thermal cycling conditions involved incubation at
50°C for 2 min followed by 94°C for 3 min, then 45 cycles
of 94°C for 30 s, 30 s at the appropriate annealing
temperature (64.5°C for MMP2 and MMP9; 61.4°C for
TIMP-1, TIMP-2, and p38MAPK; and 58°C for GADPH),
and 75°C for 45 s. After the 45th cycle, samples were incu-
bated at 72°C for 10 s, then at 65°C for 5 s, and the
temperature raised to 95°C to complete the assay. The fold
change in mRNA expression levels were assessed using
the 2−ΔΔCt method [ΔΔCt = (Ct1 −Ct2)− (Ct3 −Ct4)]. Ct1
and Ct2 represent the critical cycle numbers for the targetgene and GADPH, respectively, in the β2GP I, reduced
β2GP I and diabetic control groups, respectively. Ct3 and
Ct4 represent the critical cycle numbers for the target gene
and GADPH, respectively, in the normal control group.
Western blotting assays
Aortas were dissolved and the concentration of total pro-
tein was determined using BCA reagents (thermo scientific,
USA) according to the manufacturer’s instructions. We
added 30 μg of sample protein per 20 μL to a sodium dode-
cyl sulfate polyacrylamide gel electrophoresis buffer. The
concentration of polyacrylamide gels used was dependent
on the molecular weight of the protein examined. Gel con-
centrations were 10% for MMP2 (72 kDa, Proteintech,
USA), p38MAPK and phosphorylated p38MAPK (38 kDa,
Cell Signaling Technology, USA), β-tubulin (55 kDa, Sigma,
USA), and 15% for TIMP-1 (28 kDa, Proteintech, USA),
TIMP-2 (21 kDa, Santa Cruz, USA). Proteins were electro-
phoresed (110 V) and transferred to nitrocellulose mem-
branes, then incubated at room temperature with 5% (w/v)
skim milk in Tris-buffered saline with Tween 20 (TBST)
for 1.5 h. Membranes were incubated overnight at 4°C with
Figure 3 Morphological changes in blood vessels for the
complex-dose groups. Aortas were carefully dissected from the
iliac bifurcation to the aortic arch and external fatty deposits were
removed. Complete aortas were collected at day 43 (complex-dose
group), with five aortas selected from each group, and observed by
light microscopy following HE staining (200× magnification). In the
diabetic control group, the vascular wall had thickened and
atherosclerotic plaques were present. Plaque surfaces had a fibrous
cap (red arrow). Under the fibrous cap, there were a large number
of foam cells along with formation of white cholesterol crystals
(green arrow). In the reduced β2GP I group, the structure of the
vessel wall was intact (yellow arrow), with no thickening of the
endothelium and no significant foam cell formation.
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lated p38MAPK (all diluted 1:1000), TIMP-2 (1:100), and
β-tubulin (1:5000) diluted in TBST. Membranes were
washed with TBST (3 × 15 min) and incubated at room
temperature with the appropriate secondary antibody
(1:20,000) for 1 h. Membranes were washed with TBST
(5 × 10 min) and immunoreactive bands were detected
using enhanced chemiluminescence reagents followed by
image analysis with ImageJ.
Statistical analysis
We used SPSS19.0 to analyze our data, with values
expressed as mean ± standard deviation. Analysis of
variance was used for mono- and complex-dose groups.
If there was statistical significance then we conducted
post-hoc analyses with the diabetic control group as a
reference using Dunnett’s test. A P-value less than 0.05
was considered statistically significant.
Results
Blood glucose and body weight
The weight of mice in the diabetic groups declined and
then gradually increased (data not shown). Table 2
shows the blood glucose levels and body weight of mice
the day before they were sacrificed. There was no differ-
ence in body weight among groups (P = 0.47 in mono-
dose, P = 0.43 in complex-dose). Blood glucose levels in
mice of the diabetic groups were significantly higher
than those in the normal control group (P = 0.03 in
mono-dose, P = 0.02 in complex-dose), with no differ-
ence for mice in the diabetic groups (P = 0.51 in mono-
dose, P = 0.35 in complex-dose).
Reduced β2GP I diminished LDL-c levels
Lipid indicators were highest in the diabetic control group,
with total cholesterol (P = 0.08 in mono-dose, P = 0.12 in
complex-dose) and triglycerides (P = 0.22 in mono-dose,
P = 0.09 in complex-dose) not statistically significant
(Figure 1A–B). Although HDL-c levels in the β2GP I
and reduced β2GP I mice of the complex-dose groups
were higher than those in the diabetic control group,
these were not statistically significant (P = 0.23 in
mono-dose, P = 0.15 in complex-dose; Figure 1C).
LDL-c levels in the reduced β2GP I mice of mono- and
complex-dose groups were lower than those in the dia-
betic control group (P = 0.02 in mono-dose, P = 0.01 in
complex-dose; Figure 1D). LDL-c levels were lower in
the β2GP I mono-dose group compared with those in
the diabetic control group (P = 0.04; Figure 1D).
Aortic lipid analysis
From the aortic cross-sectional view, there was obvious red
in the diabetic control group, indicative of lipid deposition.
Lipid deposition was also seen in the arterial walls of micein the β2GP I group (complex-dose). There was no signifi-
cant lipid deposition in mice of the reduced β2GP I and
normal control groups (Figure 2A). Aortic lipid deposition
in the reduced β2GP I group was significantly less than that
in the diabetic control group (P = 0.01 in mono-dose,
P = 0.01 in complex dose; Figure 2B). Aortic lipid de-
position in mice of the β2GP I group was more pro-
nounced than in the reduced β2GP I group (P = 0.01 in
mono-dose, P = 0.03 in complex-dose; Figure 2B).
Morphological changes in aortas
There were no significant vascular morphological changes
in the mono-dose groups (data not shown). In the diabetic
control mice from the complex-dose group, aortic lipid pla-
ques were seen as evidenced by fibrous cap formation.
Many foam cells were seen under the fibrous cap. In the re-
duced β2GP I group the structure of the vessel wall was in-
tact, the endothelium showed no thickening, and there was
no significant foam cell formation (Figure 3).
Effects of reduced β2GP I on aortic mRNA and protein
expression levels
The mRNA expression levels for MMP2, MMP9, and
TIMP-1 were highest in mice of the diabetic control
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complex-dose, Figure 4A; MMP9: P = 0.02 in mono-
dose, P = 0.01 in complex-dose, Figure 4B; TIMP-1: P =
0.04 in mono-dose, P = 0.03 in complex-dose, Figure 4D).
Reduced β2GP I down-regulated MMP2, MMP9, TIMP-
1, TIMP-9 mRNA expression. For the complex-dose
group at day 42, expression was lowest (MMP2: P = 0.01;
MMP9: P = 0.01; TIMP-1, P = 0.02; TIMP-9: P = 0.03;
Figure 4A–D). MMP2/TIMP2 and MMP9/TIMP1 ex-
pression ratios showed that reduced β2GP I could sup-
press the system; these were decreased by 50.3% and
75.2% respectively for the mono-dose group, and 52.6%
and 50.3% respectively for the complex-dose group
compared with diabetic controls. β2GP I also reduced
MMP2/TIMP2 and MMP9/TIMP ratios by 25.8% and
28.6% (mono-dose) respectively, and 6.5% and 13.3%
(complex-dose) respectively compared with diabetic con-
trols (MMP2/TIMP2: P = 0.04 in mono-dose, P = 0.03 in
complex-dose; MMP9/TIMP1: P = 0.03 in mono-dose;
P = 0.04 in complex-dose; Figure 4E–F).Figure 4 Effects of reduced β2GP I on aortic MMP2, MMP9, TIMP-1, an
(mono-dose groups) and day 43 (complex-dose groups) with ten aortas se
PCR. GADPH was selected as the internal control. A. MMP2. B. MMP9. C. TIM
controls; #P < 0.05 vs. diabetic controls; @P < 0.05 vs. reduced β2GP I (R-β2GMMP2, TIMP-1, TIMP-2 protein expression levels for
mono-dose and complex-dose mice in the reduced β2GP
I group were lower than those in the diabetic control group
(MMP2: P = 0.04 in mono-dose, P = 0.03 in complex-dose,
Figure 5A; TIMP-1: P = 0.04 in mono dose, P = 0.04 in
complex dose, Figure 5B; TIMP-2: P = 0.04 in mono-dose,
P = 0.04 in complex-dose, Figure 5C). MMP2/TIMP-2 ra-
tios in the reduced β2GP I group were decreased by 12.5%
(mono-dose) and 37.4% (complex-dose) compared with the
diabetic control group, decreased by 26.2% (complex-dose)
compared with the normal control group, and decreased by
16.2% (complex-dose) compared with the β2GP I group
(MMP2/TIMP-2: P = 0.04 in mono-dose, P = 0.03 in
complex-dose; Figure 5D).
Reduced β2GP I down-regulated the p38MAPK signaling
pathway in aortas
Expression of p38MAPK mRNA and protein were in-
creased in the diabetic control group. Expression of
p38MAPK mRNAs in the reduced β2GP I group wered TIMP-2 mRNA expression levels. Aorta was sampled at day 22
lected from each group after treatment and then assessed by real time
P-2. D. TIMP-1. E. MMP2/TIMP-2. F. MMP9/TIMP-1. *P < 0.05 vs. normal
P I); and &P < 0.05 vs. β2GP I.
Figure 5 Effects of reduced β2GP I on aortic MMP2, TIMP-1, and TIMP-2 protein expression levels. Aorta was sampled at day 22 (mono-dose
groups) and day 43 (complex-dose groups) with ten aortas selected from each group after treatment and then assessed by Western Blotting. β-Tublin
was selected as the internal control. A. MMP2. B. TIMP-1. C. TIMP-2. D. MMP2/TIMP-2. *P < 0.05 vs. normal controls; #P < 0.05 vs. diabetic controls; @P < 0.05
vs. reduced β2GP I (R-β2GP I); and &P < 0.05 vs. β2GP I.
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plex-dose) compared with those in the diabetic control
group (P = 0.01 in mono-dose, P = 0.03 in complex-dose;
Figure 6A). The ratio of phosphorylated p38MAPK protein
to total p38MAPK protein in the reduced β2GP I group
was decreased by 11.5% (complex-dose) compared with
those in the diabetic control group (P = 0.04; Figure 6B).
Discussion
β2GP I and oxLDL-c can form a complex in the body
that acts as an antigen to promote arteriosclerosis. β2GP
I and CD4+ lymphocytes and monocyte-derived macro-
phages co-localize to human atherosclerotic sites. This
indicates that oxLDL-c/β2GP I and β2GP I antibodies
are higher in acute coronary syndrome patients as ad-
verse reactions increase [13]. Our previous study results
have shown that oxLDL-c/β2GP I /CRP complexes pro-
mote macrophages that have internalized oxLDL-c to
form foam cells. This accelerates the formation ofatherosclerosis in diabetic mice [6]. Results from our
previous study also showed that endothelial cells can se-
crete thioredoxin-1 to change β2GP I into reduced β2GP
I. This is generated when the functional disulfide
(Cys288-Cys326) is opened and free sulfhydryl groups
are present in domain V, playing a role in endothelial
protection during oxidative stress in vitro. We also
found that β2GP I and reduced β2GP I are present in the
plasma [7]. Studies have shown elevated β2GP I levels in
the plasma of type 2 diabetic patients [14]. However,
another study showed that the level of β2GP I was not
different between diabetic and non-diabetic patients
matched for age, sex and body mass index. These results
indicated that β2GP I levels rose in diabetic patients with
obesity and metabolic syndromes [15].
When plaques are present in blood vessels of diabetic
patients, the greatest hazard is plaque rupture [16]. A
reason for plaque instability is its thin fibrous cap.
MMPs are a class of widespread endopeptidases, whose
Figure 6 Reduced β2GP I down-regulated the p38MAPK signaling pathway in aortas. Aorta was sampled at day 22 (mono-dose groups)
and day 43 (complex-dose groups) with ten aortas selected from each group after treatment and then assessed by real time PCR (GADPH was
selected as the internal control) and Western Blotting (β-Tublin was selected as the internal control). A. Relative fold change in p38MAPK mRNA
levels. B. Ratio of phosphorylated p38MAPK to p38MAPK protein. *P < 0.05 vs. normal control; #P < 0.05 vs. diabetic controls; @P < 0.05 vs. reduced
β2GP I (R-β2GP I); and &P < 0.05 vs. β2GP I.
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lagen IV is an important component at the bottom of
the plaque base and the fibrous cap. Collagen IV is de-
graded by MMP2 and MMP9, resulting in vascular
smooth muscle cells moving from the intermediate
membrane to the intimal membrane, causing fibrous
cap thinning and plaque instability. Levels of MMP2,
MMP9, TIMP-1 and TIMP-2 are all increased in diabetic
patients with dyslipidemia or with acute coronary syn-
drome [17-19].
Our previous in vitro studies suggested reduced β2GP
I inhibits oxLDL-induced macrophages from forming
foam cells and from inducing apoptosis, however β2GP I
did not have this effect [12]. This raises the question
whether early intervention with β2GP I and reduced
β2GP I provides vascular protection in high glucose and
high fat animals in vivo, and whether β2GP I and re-
duced β2GP I can affect MMPs/TIMPs in the aorta.
These mechanisms remain unknown and further re-
search is required.
In the current study, diabetic mice models were suc-
cessfully induced. Following treatment with β2GP I and
reduced β2GP I for three weeks or six weeks, LDL-c in
the reduced β2GP I group was lower than that in the
diabetic control group. Our results suggest that long-
term application of reduced β2GP I reduces plasma
LDL-c levels.
Patients with diabetes are more prone to atheroscler-
osis and cardiovascular events [3,4]. In our study, lipid
deposition in diabetic mice was demonstrated in the
aorta along with atherosclerotic plaques. Total β2GP I
levels (oxidized and reduced form) in the plasma of
stroke patients, and old patients with heart disease, weresignificantly decreased, and this did not alter after
6 weeks [20]. Further studies have suggested high levels
of total β2GP I can reduce the risk of myocardial infarc-
tion in people older than 60 [21]. In our study, treatment
with β2GP I resulted in arterial lipid deposition but no
plaque formation in blood vessels. However, treatment
with reduced β2GP I showed that arterial lipid depos-
ition was significantly decreased and plaques in blood
vessels had not formed. These results suggest that re-
duced β2GP I can prevent atherosclerosis in diabetic
mice.
High glucose levels caused endothelial cells to express
higher levels of MMP1, MMP2 and MMP9, however
TIMP-1 levels were unaltered in vitro [22]. Plasma levels
of MMPs and TIMPs change in diabetic patients, but
these changes are inconsistent across different studies
[23-28]. Papazafiropoulou et al. reported that plasma
concentrations of MMP-2 and MMP-9 were not differ-
ent between diabetic and non-diabetic patients, while
TIMP-1 levels were lower in diabetic patients. No sig-
nificant associations were found between the expression
of MMPs and TIMP-1 and arterial stiffness; duration of
diabetes emerged as the strongest predictor of arterial
stiffness [29]. Uemura reported that diabetes increased
the activity of MMP9 via oxidative stress, resulting in in-
creased vascular complications. The probability of these
vascular complications occurring was reduced by lower-
ing the activity of MMP9 with antioxidants [30]. In our
study, MMP2, MMP9 and TIMP-1 expression in the
aortas of diabetic mice were increased. After early inter-
vention with β2GP I and reduced β2GP I, expression
levels of MMP2, MMP9, TIMP-1, and TIMP-2 were de-
creased, with reduced β2GP I having a more pronounced
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and have anti-atherogenic effects. TIMP-1 overexpres-
sion in ApoE-deficient atherosclerotic mice can prevent
plaque rupture of vein grafts [31]. The ratio of MMPs to
TIMPs have an effect on atherosclerotic processes
in vivo; TIMP-1 mainly inhibits MMP9, while TIMP-2
mainly inhibits MMP2 [10,11]. The ratios of MMP2 to
TIMP-2 and MMP9 to TIMP-1 are used to represent
the total activities of MMPs. In our study, these ratios
declined after intervention with reduced β2GP I and
β2GP I.
To explore further vascular protective mechanisms of
reduced β2GP I, we investigated the p38MAPK signaling
pathway. Results from our previous study confirmed that
reduced β2GP I plays a role in p38MAPK signaling [6].
The promoter upstream of MMPs and TIMPs exists as a
cis-acting element and is associated with signaling mole-
cules of the p38MAPK signaling pathway. Activation or
inhibition of MMP and TIMP expression is not always
consistent [32,33]. Our findings showed that reduced
β2GP I down regulated the p38MAPK pathway in aortas.
Conclusions
Reduced β2GP I reduces LDL-c levels, inhibits the for-
mation of plaques, inhibits MMPs/TIMPs ratios in the
aorta, and plays a role in vascular protection in diabetic
mice. This is probably only one portion of the mechan-
ism(s) involved. MMP2, MMP9, TIMP-1, and TIMP-2
DNA contain GC-rich islands [34,35], and it is necessary
to further investigate whether reduced β2GP I can affect
methylation of MMPs/TIMPs.
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